
- BioPharm International-03-15-2018
- Volume 2018 eBook
- Issue 1
Bigger is Better in Samsung's Approach to Biomanufacturing
A different perspective on controlling fixed costs of biomanufacturing, based on know-how from other industries, provides a competitive edge, says the CEO of Samsung BioLogics.
Digital technologies and information sciences have helped advanced medical science and research, a lesson that was obvious to Dr. Tae Han Kim, CEO and president of Samsung BioLogics, when he was researching new business areas for Samsung about 10 years ago. His recommendation-to enter the biologics drug contract manufacturing market, an area in which it had no prior experience-leveraged the company’s manufacturing and plant construction expertise and has provided the company a competitive edge, he says, in the contract manufacturing market.
View other articles in
Article Details
BioPharm International
eBook: Outsourcing Resources 2018
March 2018
Pages: 24–26
Citation
When referring to this article, please cite it as R. Peters, “Bigger is Better in Samsung’s Approach to Biomanufacturing," BioPharm International Outsourcing Resources eBook (March 2018).
Articles in this issue
over 7 years ago
Quality Oversight During Sterile Filling Operationsover 7 years ago
Good Quality Agreements Support Compliance with CGMPover 7 years ago
Gaining Analytical Insight in the Development of Biologicsover 7 years ago
Contract Services Investment Updateover 7 years ago
Process Validation in Biologics Developmentover 7 years ago
Choosing an Analytical Partner in Early Drug Developmentover 7 years ago
Outsourcing: Does Focus Pay Off?over 7 years ago
Avoiding Complete Response LettersNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.